| References: 1. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18: 297-301. 2. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:
533-538. 3. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44. 4. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209-227. 5. Byers MR, Bonica JJ. Peripheral pain mechanisms and nociceptor plasticity. In: Loeser JD, ed. Bonica's Management of Pain. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:26-29. 6. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45(suppl 9):S17-S25; S35-S36. 7. Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. Today Ther Trends: 2000;18:1-20. 8. Panlilio LM, Christo PJ, Raja SN. Current management of postherpetic neuralgia. The Neurologist. 2002;8:339-350. 9. Data on File (Davies et al). 10. Data on File (Burch, F). 11. Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3(4):1-10. 12. LidodermŽ Complete Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2002. 13. Data on File (24-hour PK study).
The LIDODERM® patch is a registered trademark of Hind Health,
Inc.
|
